Gri Bio
Biotechnology, 8954 Rio San Diego Drive, San Diego, California, 92108, United States, 1-10 Employees
Phone Number: 61********
Who is GRI BIO
GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designe...
Read More
-
Headquarters: 8954 Rio San Diego Drive, San Diego, California, 92108, United States
-
Date Founded: 2009
-
Employees: 1-10
-
Revenue: Under $1 Million
-
Active Tech Stack: See technologies
-
CEO:
Marc Hertz
Email
Phone
Industry: Biotechnology
SIC Code: 2836
|
NAICS Code: 541714 |
Show More
GRI Bio Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding GRI Bio
Answer: GRI Bio's headquarters are located at 8954 Rio San Diego Drive, San Diego, California, 92108, United States
Answer: GRI Bio's phone number is 61********
Answer: GRI Bio's official website is https://gribio.com
Answer: GRI Bio's revenue is Under $1 Million
Answer: GRI Bio's SIC: 2836
Answer: GRI Bio's NAICS: 541714
Answer: GRI Bio has 1-10 employees
Answer: GRI Bio is in Biotechnology
Answer: GRI Bio contact info: Phone number: 61******** Website: https://gribio.com
Answer: GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of NKT cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type 1 invariant NKT (iNKT) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 NKT agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Powered by
Sign in to CIENCE GO Data to uncover contact details
Free credits every month